Werth Lab
@werthlab
Followers
550
Following
647
Media
68
Statuses
396
The Autoimmune Skin Disease Unit @Penn Lab of Dr. Victoria Werth #dermatomyositis #lupus #blistering Managed by lab members
Philadelphia, PA
Joined April 2021
Our latest article by, Pain and itch in cutaneous #lupus erythematosus, is now available online in @JAADjournals an important study to understand impact of #CLE related #pain and #itch on patient quality of life #QoL!
jaad.org
Cutaneous lupus erythematosus (CLE) is a chronic inflammatory autoimmune disease that may be categorized and subtyped based on clinical characteristics (Table I). Few studies include pain and itch as...
0
0
1
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: https://t.co/56eOK86lmn ℹ️ See additional content and resources on this guideline at https://t.co/PVEyOkY14w
1
126
322
CONGRESS | #ACR25 | PRESENTATION Victoria Werth, University of Pennsylvania, discusses applying the 2025 ACR guidelines to the treatment and management of cutaneous lupus; highlighting the considerations for clinical practice using two patient case examples. Key recommendations
lupushub.com
Catch up with our live social media coverage of lupus from the American College of Rheumatology (ACR) Convergence 2025.
0
1
1
Another busy rheum-derm clinic in the books with many residents, researchers, and students! We’re looking forward to seeing everyone at @RheumDermSoc meeting and #ACR2025 @ACRheum
0
0
3
This w'end #MIHRA leadership in Dallas #MyoCon. @werthlab rec'd Science Award‼️ Intro'd by past recipient& MIHRA board member @HeleneAlex1969 MIHRA Mayo board members FloranneErnste & @ElieNaddaf3 rec'd Care Award‼️ Creating a World Where We Cure Myositis Together ✨️❤️ 🧡💛✨️
0
2
7
A commentary by Touraj Khosravi-Hafshejani & Victoria Werth "Serum IFNα as a Biomarker for Cutaneous Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application" https://t.co/3BiJbX8DqQ
#JIDJournal #DermatologyJournal #dermatology
1
1
7
The role of multicriteria decision analysis in the development of candidate classification criteria for antisynthetase syndrome: analysis from the CLASS project @eular_ARD
0
0
1
Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review https://t.co/2mckEFaC8t
#dermatomyositis @JuliePaikMD @RheumatologyUK
academic.oup.com
Abstract. Myositis, or idiopathic inflammatory myopathy, encompasses a group of autoimmune diseases with broad-spectrum clinical presentations, with a comm
0
3
7
Part B of the LILAC study of litifilimab for cutaneous #lupus erythematosus: a plain language summary #CLE @tandfonline
https://t.co/KhvdNo0snw
tandfonline.com
Published in Immunotherapy (Vol. 17, No. 3, 2025)
0
0
2
Inter-Rater and Intra-Rater Reliability of the Cutaneous #Lupus Activity-Investigator Global Assessment-Revised Instrument in @theJIDJournal @UTSWDerm
0
0
5
Serum IFNα as a Biomarker for Cutaneous #Lupus: Insights into Disease Activity, Severity, Therapeutic Monitoring and Clinical Trial Application in @theJIDJournal by Touraj Khosravi!
jidonline.org
Cutaneous lupus erythematosus (CLE) is a relapsing and remitting diverse autoimmune skin disease that can exist as an independent entity or occur as a manifestation of systemic lupus erythematosus...
0
0
2
📢 “There has not been a single approved drug for cutaneous #lupus in 75 years,” said Dr. Victoria P. Werth @werthlab. Read the Healio Exclusive story @HealioRheum @HealioDerm 👇 https://t.co/cd15HU1Vcq
0
2
3
Development and Evaluation of the #Dermatomyositis Outcomes for Muscle and Skin as an Outcome Measure in Dermatomyositis Clinical Trials in @theJIDJournal JID Innovations
jidinnovations.org
The Total Improvement Score (TIS), which is used as the primary efficacy measure in dermatomyositis (DM) clinical trials, lacks a skin-specific measure. However, skin is a defining feature of DM. In...
0
0
1
Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with #dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial in @TheLancet
thelancet.com
Dazukibart resulted in a pronounced reduction in disease activity and was generally well tolerated, supporting IFNβ inhibition as a highly promising therapeutic strategy in adults with dermatomyosi...
0
0
2
Erythema variation in #dermatomyositis across subtypes and racial groups: importance of outcome measure for dermatomyositis clinical trials in @BrJDermatol
academic.oup.com
Two measurement tools are currently used to assess skin disease activity in dermatomyositis (DM) clinical trials: the Cutaneous Dermatomyositis Disease Are
1
1
2
Risk of interstitial lung disease in adult patients with #dermatomyositis treated with methotrexate: A retrospective analysis of a prospective cohort in @JAADjournals
0
0
2
#Smoking status is a negative predictor of six-month cutaneous #lupus activity trends: A prospective cohort study in @JAADjournals by Tyler Cepica and investigators from the Chong Lab @UTSWDerm and from our group!
0
1
7
Subtype and Racial Erythema Variation for Cutaneous #Lupus Trials by Lillian Xie and others from our group in @JAMADerm #DermTwitter
https://t.co/lpk0HRlTkR
jamanetwork.com
This cross-sectional study assesses cutaneous lupus erythematosus severity scores by disease subtype and patient self-reported race to determine whether differences affect eligibility for erythema...
0
1
5